These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 38152089)

  • 1. Guideline for the management of myasthenic syndromes.
    Wiendl H; Abicht A; Chan A; Della Marina A; Hagenacker T; Hekmat K; Hoffmann S; Hoffmann HS; Jander S; Keller C; Marx A; Melms A; Melzer N; Müller-Felber W; Pawlitzki M; Rückert JC; Schneider-Gold C; Schoser B; Schreiner B; Schroeter M; Schubert B; Sieb JP; Zimprich F; Meisel A
    Ther Adv Neurol Disord; 2023; 16():17562864231213240. PubMed ID: 38152089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Myasthenia in adults, children, and adolescents: what's new?].
    Stascheit F; Della Marina A; Meisel A
    Nervenarzt; 2023 Jun; 94(6):501-509. PubMed ID: 36995386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paraneoplastic syndromes of the neuromuscular junction: therapeutic options in myasthenia gravis, lambert-eaton myasthenic syndrome, and neuromyotonia.
    van Sonderen A; Wirtz PW; Verschuuren JJ; Titulaer MJ
    Curr Treat Options Neurol; 2013 Apr; 15(2):224-39. PubMed ID: 23263888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efgartigimod improves muscle weakness in a mouse model for muscle-specific kinase myasthenia gravis.
    Huijbers MG; Plomp JJ; van Es IE; Fillié-Grijpma YE; Kamar-Al Majidi S; Ulrichts P; de Haard H; Hofman E; van der Maarel SM; Verschuuren JJ
    Exp Neurol; 2019 Jul; 317():133-143. PubMed ID: 30851266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapy in myasthenia gravis and Lambert-Eaton myasthenic syndrome.
    Newsom-Davis J
    Semin Neurol; 2003 Jun; 23(2):191-8. PubMed ID: 12894384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome.
    Maddison P; McConville J; Farrugia ME; Davies N; Rose M; Norwood F; Jungbluth H; Robb S; Hilton-Jones D
    J Neurol Neurosurg Psychiatry; 2011 Jun; 82(6):671-3. PubMed ID: 20392977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic, serological and clinical evaluation of childhood myasthenia syndromes- single center subgroup analysis experience in Turkey.
    Özsoy Ö; Cinleti T; Günay Ç; Sarıkaya Uzan G; Giray Bozkaya Ö; Çağlayan AO; Hız Kurul S; Yiş U
    Acta Neurol Belg; 2023 Dec; 123(6):2325-2335. PubMed ID: 37656362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update in the Management of Myasthenia Gravis and Lambert-Eaton Myasthenic Syndrome.
    Bodkin C; Pascuzzi RM
    Neurol Clin; 2021 Feb; 39(1):133-146. PubMed ID: 33223079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myasthenia gravis Lambert-Eaton overlap syndrome.
    Oh SJ
    Muscle Nerve; 2016 Jan; 53(1):20-6. PubMed ID: 26418033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myasthenia and the neuromuscular junction.
    Gilhus NE
    Curr Opin Neurol; 2012 Oct; 25(5):523-9. PubMed ID: 22892950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Myasthenia, from the internist's point of view].
    Eymard B
    Rev Med Interne; 2014 Jul; 35(7):421-9. PubMed ID: 24112993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autoimmune mediated neuromuscular junction defects.
    Farrugia ME; Vincent A
    Curr Opin Neurol; 2010 Oct; 23(5):489-95. PubMed ID: 20651592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IVIg in myasthenia gravis, Lambert Eaton myasthenic syndrome and inflammatory myopathies: current status.
    Illa I
    J Neurol; 2005 May; 252 Suppl 1():I14-8. PubMed ID: 15959667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myasthenia Gravis and Lambert-Eaton Myasthenic Syndrome: New Developments in Diagnosis and Treatment.
    Pascuzzi RM; Bodkin CL
    Neuropsychiatr Dis Treat; 2022; 18():3001-3022. PubMed ID: 36578903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myasthenia Gravis and Congenital Myasthenic Syndromes.
    Ciafaloni E
    Continuum (Minneap Minn); 2019 Dec; 25(6):1767-1784. PubMed ID: 31794470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders.
    Punga AR; Maddison P; Heckmann JM; Guptill JT; Evoli A
    Lancet Neurol; 2022 Feb; 21(2):176-188. PubMed ID: 35065040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myasthenia gravis and congenital myasthenic syndromes.
    Gilhus NE
    Handb Clin Neurol; 2023; 195():635-652. PubMed ID: 37562891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Myasthenia gravis and myasthenic syndromes].
    Marouf W; Sieb JP
    Z Rheumatol; 2009 Aug; 68(6):465-70. PubMed ID: 19609783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efgartigimod as Rescue Medication in a Patient with Therapy-Refractory Myasthenic Crisis.
    Alhaj Omar O; Diel NJ; Gerner ST; Mück A; Huttner HB; Krämer-Best HH
    Case Rep Neurol Med; 2024; 2024():9455237. PubMed ID: 38939234
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.